COVID-19 (SARS-CoV-2 infection) Infections and Infestations COVID-19 (SARS-CoV-2 infection)
Conditions
Interventions
This is a retrospective cohort study using linked secondary databases in England accessed through the NHS Digital Trusted Research Environment (TRE). The primary care data will be linked with vaccinat
Sponsors
AstraZeneca (United States)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. People in England who have received at least one dose of the Oxford/AstraZeneca COVID-19 vaccine (the AstraZeneca vaccine arm) or at least one dose of the Pfizer COVID-19 vaccine (the Pfizer vaccine arm) 2. People in England who were not vaccinated with any COVID-19 vaccine during the same time period (concurrent control arm) or during March-December 2020 (historical control arm) who were matched to the vaccinated individuals by age, gender, region, and comorbidity 3. All ages
Exclusion criteria
Exclusion criteria: Primary analysis: People with a history of COVID-19 infection (confirmed by RT-PCR or not) prior to vaccination. This group of people is not excluded in the sensitivity analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured using linked secondary databases in England accessed through the NHS Digital Trusted Research Environment (TRE) at a single time point: 1. Rate of hospitalizations associated with COVID-19 2. Rate of admission to ICU associated with COVID-19 3. Rate of mortality associated with COVID-19 | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured using linked secondary databases in England accessed through the NHS Digital Trusted Research Environment (TRE) at a single time point: 1. Rate of any hospitalizations 2. Rate of any admission to ICU 3. Overall mortality rate | — |
Countries
England, United Kingdom
Contacts
Public ContactSimon de Lusignan
Outcome results
None listed